UroGen Pharma Financials
| URGN Stock | USD 11.66 0.13 1.13% |
UroGen |
UroGen Pharma Stock Summary
UroGen Pharma competes with Inhibrx, Celcuity LLC, Enliven Therapeutics, Ikena Oncology, and Xilio Development. UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey. Urogen Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 201 people.Specialization | Healthcare, Biotechnology |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | IL0011407140 |
| CUSIP | M96088105 |
| Location | Israel |
| Business Address | 400 Alexander Park |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.urogen.com |
| Phone | 646 768 9780 |
| Currency | USD - US Dollar |
UroGen Pharma Key Financial Ratios
| Return On Equity | -14.81 | ||||
| Return On Asset | -0.26 | ||||
| Target Price | 34.86 | ||||
| Number Of Employees | 235 | ||||
| Beta | 1.13 |
UroGen Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining UroGen Pharma's current stock value. Our valuation model uses many indicators to compare UroGen Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across UroGen Pharma competition to find correlations between indicators driving UroGen Pharma's intrinsic value. More Info.UroGen Pharma is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the UroGen Pharma's earnings, one of the primary drivers of an investment's value.UroGen Pharma Systematic Risk
UroGen Pharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. UroGen Pharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on UroGen Pharma correlated with the market. If Beta is less than 0 UroGen Pharma generally moves in the opposite direction as compared to the market. If UroGen Pharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one UroGen Pharma is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of UroGen Pharma is generally in the same direction as the market. If Beta > 1 UroGen Pharma moves generally in the same direction as, but more than the movement of the benchmark.
UroGen Pharma March 20, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of UroGen Pharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of UroGen Pharma. We use our internally-developed statistical techniques to arrive at the intrinsic value of UroGen Pharma based on widely used predictive technical indicators. In general, we focus on analyzing UroGen Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build UroGen Pharma's daily price indicators and compare them against related drivers.
| Downside Deviation | 3.22 | |||
| Information Ratio | 0.0898 | |||
| Maximum Drawdown | 12.01 | |||
| Value At Risk | (4.57) | |||
| Potential Upside | 4.63 |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UroGen Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.